Findings from CONFIRM - a large real-world evidence study - compared the effectiveness of Tresiba injections versus insulin glargine U300, marketed as Toujeo and sold by Sanofi. The study included ...
Sanofi is hitting back with its new insulin glargine formulation Toujeo (U300), which was filed with the European Medicines Agency in June and the FDA in July, which it hopes will continue the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback